Task V24: Cell line optimization and pre-master bank generation for a Hepatitis B Virus (HBV) vaccine

传染病疫苗和其他生物制品的生产和表征服务（MCS）合同提供了涵盖产品开发规划和可行性评估的各种服务；产品优化;I/II期临床研究的产品开发和符合cGMP的生产；技术和设施审核；以及适合提交给美国食品和药物管理局（FDA）的监管支持。这些服务将促进开发和引进新的疫苗和生物制剂，以防止潜在的生物恐怖主义病原体以及新出现和重新出现的传染病。该合同还规定了疫苗、疫苗成分（包括佐剂）、疫苗递送系统、其他生物制剂和挑战材料的生产。

The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and feasibility assessments; product optimization; product development and cGMP compliant manufacture for Phase I/II clinical studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism and emerging and re-emerging infectious diseases. This contract also provides for manufacture of vaccines, vaccine components including adjuvants, vaccine delivery systems, other biologics, and challenge material.